<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00307827</url>
  </required_header>
  <id_info>
    <org_study_id>291-418</org_study_id>
    <secondary_id>2005-003482-17</secondary_id>
    <nct_id>NCT00307827</nct_id>
  </id_info>
  <brief_title>Study of Visilizumab in Subjects With Intravenous Steroid-Refractory Ulcerative Colitis (IVSR-UC)</brief_title>
  <official_title>A Phase 2, Randomized, Double-blind, Multicenter, Dose-exploration Study of Visilizumab in Subjects With Intravenous Steroid-refractory Ulcerative Colitis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Abbott</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Abbott</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the efficacy, immunogenicity, and safety of various&#xD;
      doses of visilizumab in subjects with intravenous steroid-refractory ulcerative colitis&#xD;
      (IVSR-UC) and to evaluate optimal dosing.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PDL BioPharma, Inc. was formerly known as Protein Design Labs, Inc.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Study Canceled&#xD;
  </why_stopped>
  <start_date>April 2006</start_date>
  <completion_date type="Actual">November 2007</completion_date>
  <primary_completion_date type="Actual">November 2007</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of subjects in each of the three visilizumab dose groups who respond to treatment in the dose-exploration portion of this study (Stage 1).</measure>
    <time_frame>Day 45</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Comparison of subjects in the three visilizumab dose groups</measure>
    <time_frame>During the course of the study</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">38</enrollment>
  <condition>Ulcerative Colitis</condition>
  <arm_group>
    <arm_group_label>Arm 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Visilizumab low dose level</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Visilizumab middle dose level</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Visilizumab high dose level</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Visilizumab</intervention_name>
    <description>Visilizumab administered intravenously once per day for two days</description>
    <arm_group_label>Arm 1</arm_group_label>
    <arm_group_label>Arm 2</arm_group_label>
    <arm_group_label>Arm 3</arm_group_label>
    <other_name>NuvionÂ®; HuM291</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria&#xD;
&#xD;
        Eligible subjects will be considered for inclusion in this study if they meet all of the&#xD;
        following criteria:&#xD;
&#xD;
          -  Males and females, 18 years of age or older.&#xD;
&#xD;
          -  Diagnosis of ulcerative colitis (UC), as verified by endoscopy performed within 60&#xD;
             months prior to consent.&#xD;
&#xD;
          -  Severe active disease, as defined by modified Truelove Witts severity index (MTWSI) &gt;=&#xD;
             11 at consent, with a confirmatory MTWSI &gt;= 10 on or after the fifth consecutive day&#xD;
             of intravenous (IV) steroids and within 1 day prior to randomization.&#xD;
&#xD;
          -  Mayo score &gt;= 10 and Mayo mucosal subscore &gt;= 2 after a minimum of 3 consecutive days&#xD;
             (ie, on or after the fourth consecutive day) of IV steroids.&#xD;
&#xD;
          -  Adequate contraception from the day of consent through 3 months after the last dose of&#xD;
             study drug.&#xD;
&#xD;
          -  Negative serum pregnancy test at screening.&#xD;
&#xD;
          -  Negative Clostridium difficile test within 10 days prior to randomization.&#xD;
&#xD;
          -  Signed and dated informed consent and Health Insurance Portability and Accountability&#xD;
             Act (HIPAA) if applicable.&#xD;
&#xD;
        Exclusion Criteria&#xD;
&#xD;
        Subjects will be ineligible for this study if they meet any one of the following criteria:&#xD;
&#xD;
          -  UC requiring immediate intervention.&#xD;
&#xD;
          -  History of total proctocolectomy, or subtotal colectomy with ileorectal anastomosis&#xD;
&#xD;
          -  Presence of ileostomy.&#xD;
&#xD;
          -  White blood cell count less than 2.5 x 10^3/mcL; platelet count less than 150 x&#xD;
             10^3/mcL; or hemoglobin level less than 8 g/dL.&#xD;
&#xD;
          -  Active medically significant infections, particularly those of viral etiology, eg,&#xD;
             known cytomegalovirus (CMV) colitis. This includes any incidence of medically&#xD;
             significant opportunistic infections within the past 12 months.&#xD;
&#xD;
          -  Live vaccination within 6 weeks prior to randomization.&#xD;
&#xD;
          -  Significant organ dysfunction, including cardiac, renal, liver, central nervous system&#xD;
             (CNS), pulmonary, vascular, gastrointestinal, endocrine, or laboratory abnormality.&#xD;
&#xD;
          -  History or treatment of lymphoproliferative disorder (LPD) or malignancy within the&#xD;
             past 5 years (excluding nonmelanoma skin cancer or carcinoma in situ of the cervix).&#xD;
&#xD;
          -  Seropositivity for infection with human immunodeficiency virus (HIV-1), hepatitis B&#xD;
             virus (HBV) surface antigen, or hepatitis C virus (HCV).&#xD;
&#xD;
          -  Pregnancy or nursing.&#xD;
&#xD;
          -  Treatment with a first dose of infliximab or another anti-TNF-a drug within 4 weeks of&#xD;
             randomization, or treatment with a subsequent dose of an anti-TNF-a drug within 2&#xD;
             weeks of randomization.&#xD;
&#xD;
          -  Treatment with cyclosporine or tacrolimus (FK506) within 2 weeks prior to&#xD;
             randomization.&#xD;
&#xD;
          -  Treatment with any other investigational drugs or therapies within 60 days prior to&#xD;
             randomization, except those mentioned in the two exclusion criteria above.&#xD;
&#xD;
          -  Unwilling or unable to discontinue all UC drugs, except glucocorticoids and oral&#xD;
             5-ASA, immediately prior to randomization.&#xD;
&#xD;
          -  Nontherapeutic levels of chronic antiseizure medications in subjects with a prior&#xD;
             history of seizures.&#xD;
&#xD;
          -  Any condition that, in the investigator's opinion, makes the subject unsuitable for&#xD;
             study participation.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mihail Obrocea, MD</last_name>
    <role>Study Director</role>
    <affiliation>Abbott</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 71894</name>
      <address>
        <city>Savannah</city>
        <state>Georgia</state>
        <zip>31405</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 71897</name>
      <address>
        <city>Worcester</city>
        <state>Massachusetts</state>
        <zip>01655</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 71913</name>
      <address>
        <city>Manhasset</city>
        <state>New York</state>
        <zip>11030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 71895</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>27599-7032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 71896</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44106-5066</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 71875</name>
      <address>
        <city>Hamilton</city>
        <zip>L8N 3Z5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 71873</name>
      <address>
        <city>Winnipeg</city>
        <zip>R3A 1R9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 72338</name>
      <address>
        <city>Osijek</city>
        <zip>31 000</zip>
        <country>Croatia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 72334</name>
      <address>
        <city>Zagreb</city>
        <zip>10000</zip>
        <country>Croatia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 72345</name>
      <address>
        <city>Bologna</city>
        <zip>40138</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 72314</name>
      <address>
        <city>Moscow</city>
        <zip>111123</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 71953</name>
      <address>
        <city>Nizhny-Novgorod</city>
        <zip>603126</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 72315</name>
      <address>
        <city>St. Petersburg</city>
        <zip>196247</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 72342</name>
      <address>
        <city>St. Petersburg</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 72368</name>
      <address>
        <city>Badalona - Barcelona</city>
        <zip>08916</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 72366</name>
      <address>
        <city>Majadahonda (Madrid)</city>
        <zip>28222</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>Croatia</country>
    <country>Italy</country>
    <country>Russian Federation</country>
    <country>Spain</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Ireland</country>
    <country>Switzerland</country>
  </removed_countries>
  <verification_date>April 2012</verification_date>
  <study_first_submitted>March 24, 2006</study_first_submitted>
  <study_first_submitted_qc>March 24, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 28, 2006</study_first_posted>
  <last_update_submitted>April 26, 2012</last_update_submitted>
  <last_update_submitted_qc>April 26, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 27, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Steroid-Refractory</keyword>
  <keyword>IVSR-UC</keyword>
  <keyword>Ulcerative Colitis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colitis</mesh_term>
    <mesh_term>Colitis, Ulcerative</mesh_term>
    <mesh_term>Ulcer</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Visilizumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

